AI Doctor — Project Index
All dashboards, deep-dive analyses, and reference files for Bambos Kaisharis's longevity programme.
Dashboards
Single-pane view of all biomarkers, diagnoses, Rx + supplement stack, genomic risk profile, care team, emerging therapies, and prioritised action items. 12-module layout.
Interactive longitudinal chart of all key biomarkers (ApoB, LDL-C, Lp(a), GGT, Creatinine, HbA1c, Testosterone) across all available lab dates.
Active Protocol
Deep Dives
Single decision view across every lipid-lowering lever. Prioritised next-step decision tree (psyllium → ezetimibe → statin or bempedoic acid), full comparison matrix of 16 levers, emerging treatments (Pelacarsen, Olpasiran, Muvalaplin, Obicetrapib, VERVE-102). Includes psyllium dosing optimisation and 5-year sequence.
Real-time readiness watchlist for 7 emerging Lp(a)-lowering therapies. Tracks Phase 2/3 readouts, Bay Area clinical trial eligibility, and prioritised action protocol.
Quarterly scan of Verve/Lilly VERVE-102, Editas EDIT-401, Intellia, CRISPR Tx and Altos. VERVE-102 now published in NEJM (62% LDL-C drop, durable 18 months). Trial eligibility check against your phenotype: 0 of 7 programmes currently open to you — every one requires HeFH or premature CAD.
Single source of truth. Evidence (109-RCT meta-analysis, NHS/HPFS cohort, 2025 ESC/EAS caveat), mechanism, Lp(a) interaction, and verified Top 3 product picks (NOW CardioAid-S + Fish Oil, Nature Made CholestOff Plus, Solgar Phytosterol Complex) with side-by-side comparison and dosing protocol.
Right-fit intervention for hyperlordosis + flared ribs + winged scapula + forward head + rhomboid strain. Pattern diagnosis (Left AIC + PEC), mechanism (ZOA → diaphragm → trunk), 8-week protocol, top Palo Alto-adjacent providers, Anthem Blue Cross PPO coverage script, and side-by-side vs Rolfing (~$3,000 savings).
Foot-to-skull reference library for the self-directed calisthenics/stretching work: the 8 accelerators, a plumb-line chain map, and 5 regions (breath/ZOA, foot tripod, hip IR + APT, ribcage/serratus, neck) — each with mechanism, felt-sense cues, embedded video walkthroughs (PRI, Conor Harris, Squat University, [P]rehab), a 20–30 min daily loop, and peer-reviewed evidence.
[Archived 27 May 2026 — superseded by PRI briefing] Decision-ready briefing on Structural Integration as a 10-session protocol. NHMRC 2024 review verdict, Harvard pilot RCT, mechanism, Marcel Kempf (Palo Alto, $350/session = $3,500 total), risk profile.
Reference Files on Disk
| File | Type | Date | Notes |
|---|---|---|---|
| 2026-04-10-Kaisharis-B-…pdf | Apr 2026 | Quest lab report — April 2026 panel | |
| Oura_Biomarkers_MBP_Report_20260124.pdf | Jan 2026 | Oura / Quest biomarkers report | |
| health screen 20260324.pdf | Mar 2026 | Health screen — March 2026 | |
| health screen 20260128.pdf | Jan 2026 | Health screen — January 2026 | |
| health screen 20240411.pdf | Apr 2024 | Health screen — April 2024 baseline | |
| Scan - CT Cardiac Calcium Score CPT 75571 - Aug 2024.pdf | Aug 2024 | CAC Score = 0 · Total calcium burden zero | |
| colonoscopy screen 20240607.PDF | Jun 2024 | Resected hepatic flexure tubular adenoma — surveillance protocol active | |
| testicular ultrasound 20260310.pdf | Mar 2026 | Testicular ultrasound | |
| Genomic_Analysis_Report_Bambos_Kaisharis.docx | DOCX | May 2026 | Full Nucleus genomic risk analysis — HFE H63D, APOE, FH genes, PRS |
| data/biomarkers-longitudinal.json | JSON | May 2026 | Machine-readable longitudinal biomarker table |
| Bambos RX 2-26-26.pdf | Feb 2026 | Prescription record |
index.html.